An analysis of more than 1,000 Neisseria gonorrhoeae genomes provided insights into antibiotic resistance patterns and related genomic features.
The award will go toward development of Talis Bio's SlipChip POC technology for pathogen identification and antibiotic-susceptibility testing.
The Dublin-based company also aims to raise up to €5 million this year to support additions to its R&D and sales and marketing teams.
The company unveiled forthcoming products for high-throughput molecular testing, diagnostic lab informatics, and microbiology automation.
The ResistancePlus MG Positive Control kit was listed with the FDA for sale in the US, where it will be sold through SpeeDx's US entity.
The Artus T. vaginalis QS-RGQ kit is designed for the qualitative detection of Trichomonas vaginalis DNA purified from clinician-collected patient samples.
The test has been validated for use with the same full set of female urogenital specimens that are used with Cobas NT/NG testing, as well as for use with male urine.
The sequencing-based, laboratory-developed test, called SmartJane, contains the first commercially available vaginal microbiome assay.
The test is designed to detect and differentiate herpes simplex virus types 1 and 2, Treponema pallidum, and varicella-zoster virus.
Becton Dickinson and Euroclone aim to develop and commercialize the molecular assays for launch outside the US in 2018, and in the US at a later date.
US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.
Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.
In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.
In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.